Insulin Syringe Sizes for Peptides: What the Numbers Mean
What does U-100 mean on an insulin syringe? The FDA approved Humalog label states that U-100 insulin contains 100 units per millilitre, so one unit mark on a matching U-100 syringe equals 0.01 mL.
What needle sizes are in circulation? Pen needles range from 4 to 12.7 mm and syringe needles from 6 to 12.7 mm (insulin data, not peptide-specific).
Is there peptide-specific syringe research?No. Every technique trial located used insulin, and one needle trial's authors state that limitation themselves.
Does a thinner or shorter needle change the dose delivered? No study has measured gauge effects on delivered dose or absorption; existing findings cover leakage and pain, mostly in pigs.
Peptides Vietnam read 21 PubMed records and 9 manufacturer labels for this cluster, and marks exactly where the syringe evidence runs out.
Why is all the syringe evidence insulin evidence?
Because no technique trial using any peptide other than insulin was found for needle length, gauge, angle or skin fold, so every number on this page arrives by analogy.
The authors of the 4 mm needle trial call for further trials in other patient groups and name GLP-1 users explicitly (PMID 20429832). The GLP-1 labels for products like semaglutide and tirzepatide name injection sites but no needle length, gauge or angle. The same pattern holds in the subcutaneous versus intramuscular analysis and the how to inject peptides guide.
What do the units on a U-100 syringe actually mean?
On the FDA approved Humalog label, each unit mark on a U-100 syringe equals one hundredth of a millilitre of a 100 units per mL product.
The Humalog carton specifies:
U-100 insulin at 100 units per mL, so 1 unit on a U-100 syringe equals 0.01 mL (FDA approved Humalog label).
Disclaimer: This conversion belongs to a U-100 syringe matched to a U-100 product. It says nothing about how many milligrams of peptide sit in a unit, because that depends on the concentration in the vial.
The carton adds: "Use only with a U-100 syringe," because the scale is product-matched by design. The peptide reconstitution calculator does the vial math, and the how to take peptides page covers the wider unit confusion problem.
What syringe and needle sizes are actually in circulation?
The anatomy literature records (insulin data, not peptide-specific):
| Needle | Length |
|---|---|
| pen needles | from 4 to 12.7 mm |
| syringe needles | from 6 to 12.7 mm |
Ultrasound in 388 adults with diabetes put mean skin thickness in a narrow 1.9 to 2.4 mm band across the four injection sites, while fat thickness varied far more with sex and BMI (PMID 20429833).
In 341 more adults, skin-to-muscle distance measured a median (PMID 25329935):
| Site | Skin-to-muscle distance |
|---|---|
| the thigh | 10.9 mm |
| the buttock | 16.9 mm |
The same study then modelled the risk of reaching muscle:
An 8 mm needle at 90 degrees with no skin fold carried a modelled intramuscular risk of 25% at the thigh and 9.7% at the abdomen, against 1.6% and 0.1% for a 4 mm needle (insulin data, not peptide-specific).
Disclaimer: These percentages are modelled from measured anatomy, not observed injections, and come from insulin research.
The FITTER consensus of 183 experts from 54 countries puts the shortest needles first line, 4 mm pen and 6 mm syringe (PMID 27594187). Consensus, not a trial, and entirely insulin-focused.
Does needle length change how the dose behaves?
Within subcutaneous tissue the evidence says no, and the real risk of a long needle is crossing into muscle, not depth itself.
The clearest test comes from a clamp study whose authors' affiliation and funding are Eli Lilly, which administered:
Insulin lispro at 0.25 U/kg, injected at 5 mm and at 8 mm depth (insulin data, not peptide-specific).
Disclaimer: Pharmacokinetic and glucodynamic measures were equivalent between depths, inside the standard bioequivalence window. This tests depth inside subcutaneous tissue only, with insulin (PMID 25697717).
Two trials tested this directly. In 274 randomised obese adults, mean BMI 37, a 4 mm pen needle gave glycaemic control equivalent to 8 mm and 12.7 mm needles, with less pain and no added leakage, even at up to 350 units of insulin daily (insulin data, not peptide-specific; PMID 25662503). A second trial found 4 mm equivalent to 5 mm and 8 mm, with about two thirds preferring 4 mm (PMID 20429832).
What does the gauge evidence actually show?
Only leakage and preference findings exist, the key leakage result comes from pigs, and no study has quantified how gauge affects delivered dose or absorption.
The one leakage study found that 32G needles leaked less than 31G, that 90 degrees leaked less than roughly 45, and that waiting at least 3 seconds before withdrawal reduced leakage (PMID 26798083).
All three findings are porcine, and the authors are Novo Nordisk employees and shareholders. The human arm covered only volume, speed and region, post hoc.
From that study comes the volume ceiling community sources repeat:
A maximum of 800 microlitres per injection (insulin data, not peptide-specific).
Disclaimer: The 800 microlitre figure rests on the porcine arm plus a post hoc human analysis of volume and speed. No independent human confirmation was located.
A ten second dwell is widely taught, but no human trial supports it. The only quantified figure is the 3 second minimum, in pigs (PMID 26798083).
Why do unit systems cause real dosing errors?
Because a vial plus a syringe removes the dose-limiting feature of a metered pen, and the same product gets described in three unit systems.
A poison control centre case series documented three compounded semaglutide self-administration errors (PMID 37392810). Two patients gave themselves ten-fold overdoses.
All three had nausea, vomiting and abdominal pain lasting days. The product arrived as a vial with syringes, the dose discussed in millilitres, units and milligrams at once.
Three cases support no rate claim, but they establish the mechanism: when a vial replaces a pen, the user becomes the dosing device. That matters in Vietnam, where fake and compounded GLP-1 products circulate and clear concentration labelling from well-chosen suppliers is the practical counterweight.
How long can a multi-dose vial stay in use?
The widely repeated 28 day figure traces to the Humalog insulin label, not the bacteriostatic water label, which assigns no post-puncture dating at all.
The Humalog label specifies:
Multiple-dose vials, pens and cartridges kept for 28 days in use at room temperature up to 30 C, with unopened and opened room temperature time counted together (approved label).
Disclaimer: This is the in-use rule for one insulin product, not a rule for bacteriostatic water or a stability finding for any reconstituted research peptide.
The Bacteriostatic Water for Injection USP label specifies the preservative permitting repeated withdrawals: 0.9% benzyl alcohol in the 30 mL plastic vial and 1.1% in the 20 mL glass vial (approved label). A full-text search found no discard, 24 hour or beyond-use statement after first puncture. The bacteriostatic versus sterile water and reconstituted peptides FAQs cover the details.
No stability, sterility or potency trial exists for any reconstituted research peptide at any temperature, yet community practice refrigerates vials for weeks. See the storing peptides in Vietnam heat guide and the lyophilized peptides FAQ.
Peptides Vietnam works with Peptara Labs as a trusted supply partner for verified peptide sourcing, and we may earn from purchases made through our links.
Peptara Labs
peptaralabs.ioWhat did we check and what did we not find?
Three absences shape this page as findings. No technique trial used any peptide other than insulin. No study quantified gauge effects on delivered dose, as opposed to pain, preference or leakage. No human trial supports the ten second dwell time; the evidence figure is 3 seconds, in pigs.
For a broader format comparison, see the oral versus injectable peptides analysis.
What we left out
- A letter claiming alcohol swabs do not reduce injection infections is title-only with no abstract, so it was not cited.
- Needle reuse risk data from the lipohypertrophy meta-analysis belong to the injection technique guide.
- CDC injection safety pages returned HTTP 403 during evidence gathering.
- USP General Chapter 797 is paywalled, so no claim here rests on it.
The Short Version
The FDA approved label puts U-100 at 100 units per millilitre, so one unit mark is 0.01 mL.
A unit mark measures volume, not mass. What sits in that volume depends on the vial concentration.
Pen needles run 4 to 12.7 mm; the FITTER consensus puts 4 mm pen and 6 mm syringe first line.
A 4 mm needle matched longer needles in randomised trials, including at a mean BMI of 37.
Nobody has measured how gauge affects delivered dose. The gauge evidence is leakage and pain.
The 28 day in-use figure belongs to one insulin label, not to bacteriostatic water.
Frequently Asked Questions
What size insulin syringe is used for peptides?
No peptide-specific syringe exists in the evidence located. The labels studied match U-100 syringes to U-100 insulin, where one unit mark equals 0.01 mL. Syringe needles range from 6 to 12.7 mm, and the FITTER consensus places 6 mm first line. All of this is insulin data transferred to peptides by analogy.
What does U-100 mean?
On the FDA approved Humalog label, U-100 means the product contains 100 units per millilitre, so each unit mark on a matching U-100 syringe equals 0.01 mL. The carton also specifies use only with a U-100 syringe. The same mark measures a different mass of drug when the vial concentration changes.
Is a 4 mm needle long enough to reach subcutaneous fat?
The trial evidence says yes for the populations studied. Skin thickness measured 1.9 to 2.4 mm across injection sites, and 4 mm needles gave glycaemic control equivalent to 8 mm and 12.7 mm needles even in obese adults with a mean BMI of 37. These were insulin trials, the standing caveat for every technique figure.
Do thinner needles waste part of the dose?
No study was found measuring how needle gauge affects delivered dose or absorption. The existing gauge evidence concerns leakage and pain. In a pig model, 32G needles leaked less than 31G, in a study authored by Novo Nordisk employees and shareholders. That is a porcine leakage finding, not a human delivered-dose finding.
How many times can a bacteriostatic water vial be punctured?
The Bacteriostatic Water for Injection USP label assigns no in-use or beyond-use period after first puncture. The benzyl alcohol preservative, 0.9% or 1.1% by vial size, permits repeated withdrawals. The commonly repeated 28 day figure comes from the Humalog insulin label and applies to that product, not the diluent.
Is the ten second hold after injecting supported by evidence?
No human trial supporting a ten second needle dwell time was found. The only quantified figure located is a minimum of about 3 seconds before withdrawal, which reduced leakage in a pig model. The gap between that figure and the 10 seconds commonly taught is unexplained by the searches behind this page.
References
- Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion, 2010. Randomized controlled trial. (PMID 20429832)
- Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Current Medical Research and Opinion, 2010. Research study. (PMID 20429833)
- Intramuscular risk at insulin injection sites: measurement of the distance from skin to muscle and rationale for shorter-length needles. Diabetes Technology and Therapeutics, 2014. Comparative multicenter study. (PMID 25329935)
- Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clinic Proceedings, 2015. Randomized controlled trial. (PMID 25662503)
- Subcutaneous injection depth does not affect the pharmacokinetics or glucodynamics of insulin lispro in normal weight or healthy obese subjects. Journal of Diabetes Science and Technology, 2015. Randomized controlled trial. (PMID 25697717)
- Injection technique and pen needle design affect leakage from skin after subcutaneous injections. Journal of Diabetes Science and Technology, 2016. Randomized controlled trial. (PMID 26798083)
- New insulin delivery recommendations. Mayo Clinic Proceedings, 2016. Expert consensus recommendations. (PMID 27594187)
- Administration errors of compounded semaglutide reported to a poison control center: case series. Journal of the American Pharmacists Association, 2023. Case reports. (PMID 37392810)
- HUMALOG (insulin lispro) injection, for subcutaneous or intravenous use. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
- BACTERIOSTATIC WATER for Injection, USP. DailyMed Structured Product Label, 2026. FDA approved prescribing information.
Not medical advice. Consult a healthcare professional before starting any supplement or protocol.
Related Reading
How to Inject Peptides
Sites, angles, and what studies describe
SubQ vs Intramuscular
The boundary a long needle can cross
How to Take Peptides
Routes, timing, and reported practice
Storing Peptides in Vietnam Heat
Label ceilings against the real climate
Oral vs Injectable Peptides
What the tablet route costs in absorption
Reconstitution Calculator
Turn a vial and a volume into a syringe mark